{"id":"W2613863892","doi":"10.1177/1756287217702797","title":"Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies","year":2017,"lang":"en","type":"article","venue":"Therapeutic Advances in Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Astellas Pharma Global Development; Astellas Pharma Europe; European Association of Urology","keywords":"Mirabegron; Solifenacin; Tolterodine; Overactive bladder; Medicine; Urination; Urology; Placebo; Adverse effect; Lower urinary tract symptoms; Urinary incontinence; Internal medicine; Urinary system; Prostate","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04124651,0.001674963,0.007404153,0.001613775,0.0006531572,0.003330536,0.001492805,0.002158304,0.001766281],"category_scores_gemma":[0.03363044,0.00110185,0.01657413,0.001627945,0.001405104,0.001562187,0.001047931,0.002143231,0.000228228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002283097,"about_ca_system_score_gemma":0.002215856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000720838,"about_ca_topic_score_gemma":0.00167469,"domain_scores_codex":[0.9823461,0.01031998,0.00371121,0.001208793,0.001910522,0.000503428],"domain_scores_gemma":[0.9573641,0.02042548,0.01528624,0.002032561,0.003613965,0.001277685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.4258122,0.001342539,0.02202407,0.06680384,0.3409221,0.0003692384,0.0006311586,0.002219002,0.009867317,0.0006014912,0.002761139,0.126646],"study_design_scores_gemma":[0.2191605,0.09277501,0.08750907,0.01548157,0.5571577,0.001046613,0.0003962886,0.001968488,0.005066509,0.001415921,0.01771969,0.0003027462],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2958274,0.687521,0.004358441,0.001846852,0.0006104048,0.005636929,0.001833089,0.0001668812,0.002198887],"genre_scores_gemma":[0.9062157,0.08175372,0.004163377,0.002409966,0.0004850102,0.002671822,0.001828639,0.00007140983,0.0004003752],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.04124651,"threshold_uncertainty_score":0.2181351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03120800412144471,"score_gpt":0.4128818922531041,"score_spread":0.3816738881316594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}